Swift DX

SwiftDx is looking for companies developing biomarkers for prostate cancer

Swift DX
SwiftDx is looking for companies developing biomarkers for prostate cancer

SwiftDx’s portfolio of patented technologies enable highly sensitive lateral flow diagnostics for diseases which are undetectable with current lateral flow test technology. To accelerate SwiftDx's work in prostate cancer they are interested in making connections with companies developing feasible biomarkers.

If you are a company/academic developing suitable biomarkers, please complete the form below to register your interest.

  • Go through data wall
  • Complete embedded form
Register Your Interest

Name(Required)